89bio Inc. (ETNB)
6.28
-0.03 (-0.48%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 6.28 |
| Market Cap | 738.41M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.87 |
| PE Ratio (ttm) | -2.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7 |
| Volume | 726,566 |
| Avg. Volume (20D) | 975,552 |
| Open | 6.35 |
| Previous Close | 6.31 |
| Day's Range | 6.19 - 6.44 |
| 52-Week Range | 6.15 - 16.63 |
| Beta | undefined |
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorpor...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2019
Employees 70
Stock Exchange NASDAQ
Ticker Symbol ETNB
Website https://www.89bio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ETNB stock is "Buy." The 12-month stock price forecast is $29.5, which is an increase of 369.75% from the latest price.
Buy 71.43%
Hold 14.29%
Sell 0.00%
Next Earnings Release
89bio Inc. is scheduled to release its earnings on Feb 27, 2025,
during market hours.
Analysts project revenue of $540.00K, reflecting a n/a YoY growth and earnings per share of -0.59, making a 18.00% increase YoY.
Analysts project revenue of $540.00K, reflecting a n/a YoY growth and earnings per share of -0.59, making a 18.00% increase YoY.
